Novel Surrogate Co-Receptors for Redirected T Cell Therapy

Title: Novel Surrogate Co-Receptors for Redirected T Cell Therapy

Invention: This invention harnesses a multi-module chimeric antigen (CAR)-T approach to fight cancer or treat autoimmune diseases. A novel surrogate co-receptors can be used to tune engineered T cell receptor signaling.

Background: The demand for more personalized and potent cancer treatment is driven by harsh side effects that are considered a status quo part of treatment for current CAR-T approaches. This novel technology presents marked improvements to current CAR-T methods by providing more specific targeting.

Applications:
- Cancer treatment
- Autoimmune disease treatment

Advantages:
- Provides specific targeting
- Prevents harsh side effects

Licensing Manager:
Lisa Lin
LisaL@tla.arizona.edu
(520) 626-6969

The University of Arizona, Tucson, Arizona
Inventors

Heather Bronnimann
Graduate Student, Immunobiology

Deepta Bhattacharya
Associate Professor, Immunobiology, Immunobiology

Michael Kuhns
Assistant Professor, Immunobiology